Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Legislation (77)
- Advertising (25)
- Manufacturing (19)
- Labelling and packaging (16)
- Vaping hub (13)
- COVID-19 (11)
- Compliance and enforcement (6)
- Scheduling (national classification system) (6)
- Import and export (2)
- Clinical trials (1)
- Committees and advisory bodies (1)
- Medicinal cannabis hub (1)
- Sunscreens (1)
- Urogynaecological (transvaginal) surgical mesh hub (1)
Search
195 result(s) found, displaying 126 to 150
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesGuidance to assist sponsors when using the code tables for GMP Clearance applications
-
Regulatory decision noticesInformation to assist overseas manufactures who may undergo a remote Good Manufacturing Practice inspection during the COVID-19 pandemic
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesInformation on an exemption for radiopharmaceuticals that facilitates interstate supply during COVID-19
-
Regulatory decision noticesListed medicine ingredients and requirements have been updated.
-
Regulatory decision noticesOn 20 November 2019 the TGA issued a direction notice to Cat Media concerning its advertising of Fatblaster Clinical
-
Regulatory decision noticesA new S41BD(3) instrument has been signed to declare that some nappy rash products are not to be medical devices for the purposes of the Act
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Regulatory decision noticesNew requirements for listed medicines containing Andrographis paniculata
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Indications) Determination has been updated
-
Regulatory decision noticesTherapeutic Goods (Declared Goods) Order 2019 consolidates and replaces several instruments
-
Regulatory decision noticesJapan has recently been added to the list of Foreign Countries and Jurisdictions determined to be comparable overseas regulators
-
Regulatory decision noticesNew requirements for caffeine and caffeine-containing ingredients within listed medicines
-
Regulatory decision noticesAn amendment to the Therapeutic Goods (Permissible Ingredients) Determination commenced on 2 September 2019.
-
Regulatory decision noticesDirection Notice issued to cease advertising of therapeutic goods not entered in the ARTG
-
Regulatory decision noticesDirection Notice issued to cease advertising of unregistered therapeutic goods to consumers
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesDirection Notice issued to cease advertisement of prescription and illegal products
-
Regulatory decision noticesTGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98
-
Regulatory decision noticesTGA issues advertising direction
-
Regulatory decision noticesThis instrument applies to an application to list a complementary medicine under section 26AE of the Act.
-
Regulatory decision noticesThis instrument applies to an application to list a medicine under section 26 or 26A of the Act.
-
Regulatory decision noticesThis instrument applies to an application to register a complementary medicine